Form 4: Tourmaline Bio Director Acquires Stock Options

Director Parvinder Thiara acquired 10,000 stock options in Tourmaline Bio, Inc. on June 5, 2024, at an exercise price of $13.91.

Summary

• On June 5, 2024, Parvinder Thiara, a director of Tourmaline Bio, Inc. (TRML), acquired 10,000 stock options.
• The exercise price for these options is $13.91.
• The options vest on the earlier of the anniversary of the transaction date or the date of the Issuer's 2025 Annual Meeting of Stockholders, contingent upon continued service.
• The options expire on June 4, 2034.

Sentiment

Score: 5

Explanation: This is a neutral event. It's a standard disclosure of stock option grants to a director, which is a common practice.

Industry Context

This is a standard Form 4 filing, reflecting a change in beneficial ownership by a company insider. Such filings are common and provide transparency to the market regarding insider transactions.

Stakeholder Impact

• The acquisition of stock options by a director could be viewed positively by shareholders, as it aligns the director's interests with the company's long-term success.

Key Dates